"I am glad that taking part in a trial might help others on their own cancer journey.”
A study looking at a vaccine to prevent infection with HPV 16, HPV 18 and cancer of the cervix in young women (PATRICIA)
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial looked at a vaccine called Cervarix to prevent infection with the human papilloma viruses (HPVs) 16 and 18 in young women aged between 15 and 25.
HPVs are a group of viruses that can infect the neck of the womb (the cervix). The different viruses are given numbers to tell them apart.
Some types of HPV are called ‘high risk’ because they are linked to cervical cancer. Nearly all women with cervical cancer are found to have these high risk types of HPV. Even so, many women who have HPV do not go on to develop cervical cancer.
The HPV virus can cause the cells of the cervix to change and become abnormal. If left untreated these abnormal cells may become cancerous. Women have
When this trial was done there was no way to stop women from getting HPV. The aim of this trial was to see if Cervarix could prevent two of the ‘high risk’ types of virus, HPV 16 and HPV 18. If the vaccine worked and prevented infection with HPV 16 and 18, it could reduce the number of women who go on to develop cervical cancer.
Summary of results
The trial team found that Cervarix was useful in preventing infection with HPV 16 and HPV 18.
This trial recruited 18,644 healthy women between the age of 15 and 25.
- Half had 3 injections of the Cervarix vaccine
- Half had 3 injections of the hepatitis A vaccine – (doctors called this the ‘
All the women who took part had 3
The researchers looked at the results when 23 women in the trial had pre cancerous changes in the cervix caused by HPV 16 or HPV 18. They found
- 21 women in the control group had CIN 2 linked with HPV16 or HPV 18
- 2 women in the Cervarix group had CIN 2 linked with HPV 16 or 18
From their analysis, the researchers say that Cervarix prevented pre cancerous changes (CIN 2 or 3) caused by HPV 16 and HPV 18 in about 90% of women. They concluded that the vaccine worked well against HPV infection and could be used to help prevent cervical cancer.
The side effects for both groups were mild and included injection site reactions such as redness, pain and swelling for a few days. Some of the women who had Cervarix also had headaches and felt tired. But this went away a few days after the injections.
After 3 years, the researchers published some more results. This longer term follow up showed the vaccine continued to prevent pre cancerous changes in more than 90% of women.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial